Literature DB >> 20636406

Discontinuation of calcineurin inhibitors treatment allows the development of FOXP3+ regulatory T-cells in patients after kidney transplantation.

Jacqueline van de Wetering1, Periklis Koumoutsakos, Annemiek Peeters, Barbara J van der Mast, Petronella de Kuiper, Jan N M IJzermans, Willem Weimar, Carla C Baan.   

Abstract

This study investigated specific gene expression profiles in patients with donor-specific cytotoxic-hyporesponsiveness, reflected by cytotoxic T-lymphocyte precursor frequency (CTLpf). The effect of calcineurin inhibitor (CNI) withdrawal was studied on markers for cytotoxicity (perforin, granzyme B), apoptosis (Fas,FasL), Th1 and Th2 cytokines (IL-2, IL-10), Th1 and Th2 transcription factors (T-bet, GATA 3), Th17 transcription factor and cytokine (RORγt, IL-17), and for immune regulation/activation (CD25, FOXP3). Peripheral blood samples from renal allograft recipients (n = 18) more than two yr after transplantation with stable renal function were analyzed before and four months after CNI withdrawal. Additionally, systolic and diastolic blood pressure, cholesterol, serum creatinine and proteinuria were evaluated, and no significant differences were measured before and after CNI withdrawal. However, CNIs' discontinuation influenced peripheral gene expression profiles. After CNI withdrawal, the mRNA expression of Granzyme B, Perforin, Fas, FasL, T-bet, GATA3 and CD25 were significantly lower than during CNI treatment. After CNI discontinuation, donor-specific CTLpf decreased, while FOXP3 expression discriminated between detectable and non-detectable donor-specific cytolysis reactivity; FOXP3 transcript values were highest in absence of donor-specific cytotoxicity (p < 0.01). Our study shows CNI withdrawal in stable kidney transplant recipients two yr after transplantation is safe. Moreover, discontinuation of CNIs' treatment allows FOXP3+ regulatory T-cells development, resulting in a significant decrease of anti-donor immune reactivity.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20636406     DOI: 10.1111/j.1399-0012.2010.01311.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  10 in total

1.  Myeloid-Derived Suppressor Cells Ameliorate Cyclosporine A-Induced Hypertension in Mice.

Authors:  Valorie L Chiasson; Kelsey R Bounds; Piyali Chatterjee; Lochana Manandhar; Abhinandan R Pakanati; Marcos Hernandez; Bilal Aziz; Brett M Mitchell
Journal:  Hypertension       Date:  2017-11-13       Impact factor: 10.190

2.  Cyclosporin but not everolimus inhibits chemokine receptor expression on CD4+ T cell subsets circulating in the peripheral blood of renal transplant recipients.

Authors:  A Hoerning; S Köhler; C Jun; J Lu; J Fu; B Tebbe; S Dolff; T Feldkamp; A Kribben; P F Hoyer; O Witzke
Journal:  Clin Exp Immunol       Date:  2012-05       Impact factor: 4.330

Review 3.  Pharmacologic targeting of regulatory T cells for solid organ transplantation: current and future prospects.

Authors:  Kassem Safa; Sindhu Chandran; David Wojciechowski
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

Review 4.  Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies.

Authors:  Andrew Scott Mathis; Gwen Egloff; Hoytin Lee Ghin
Journal:  World J Transplant       Date:  2014-06-24

5.  SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection.

Authors:  Xin Zhang; Shu Han; Yindong Kang; Meng Guo; Shanjuan Hong; Fang Liu; Shangxi Fu; Liming Wang; Quan-Xing Wang
Journal:  Cell Mol Immunol       Date:  2012-08-27       Impact factor: 11.530

6.  Immunological and regenerative aspects of hepatic mast cells in liver allograft rejection and tolerance.

Authors:  Toshiaki Nakano; Chia-Yun Lai; Shigeru Goto; Li-Wen Hsu; Seiji Kawamoto; Kazuhisa Ono; Kuang-Den Chen; Chih-Che Lin; King-Wah Chiu; Chih-Chi Wang; Yu-Fan Cheng; Chao-Long Chen
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

7.  Regulatory T Cell Responses to High-Dose Methylprednisolone in Active Systemic Lupus Erythematosus.

Authors:  Alexis Mathian; Romain Jouenne; Driss Chader; Fleur Cohen-Aubart; Julien Haroche; Jehane Fadlallah; Laetitia Claër; Lucile Musset; Guy Gorochov; Zahir Amoura; Makoto Miyara
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

8.  Comprehensive phenotyping of regulatory T cells after liver transplantation.

Authors:  Anna Gronert Álvarez; Paraskevi Fytili; Pothakamuri V Suneetha; Anke R M Kraft; Christin Brauner; Jerome Schlue; Till Krech; Frank Lehner; Christoph Meyer-Heithuis; Elmar Jaeckel; Juergen Klempnauer; Michael P Manns; Markus Cornberg; Heiner Wedemeyer
Journal:  Liver Transpl       Date:  2015-01-20       Impact factor: 5.799

9.  Current Tolerance-Associated Peripheral Blood Gene Expression Profiles After Liver Transplantation Are Influenced by Immunosuppressive Drugs and Prior Cytomegalovirus Infection.

Authors:  Aafke A Duizendstra; Michelle V van der Grift; Patrick P Boor; Lisanne Noordam; Robert J de Knegt; Maikel P Peppelenbosch; Michiel G H Betjes; Nicolle H R Litjens; Jaap Kwekkeboom
Journal:  Front Immunol       Date:  2022-01-11       Impact factor: 7.561

10.  Alemtuzumab induction in pediatric kidney transplantation.

Authors:  Michael M Kaabak; Nadezda N Babenko; Dmitry V Samsonov; Valery A Sandrikov; Alexey A Maschan; Alan K Zokoev
Journal:  Pediatr Transplant       Date:  2013-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.